Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 4/20 | 0.33 |
| ▸ | NPY1R | P25929 | 2/20 | 0.33 |
| ▸ | NPY4R | P50391 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.32 |
| ▸ | CHRNG | P07510 | 1/20 | 0.32 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.32 |
| ▸ | CHRND | Q07001 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13401455 | 0.94 | GLP1R (0.38) | GLP1RFURINNPY1RNPY4RMAPT | |
| SCHEMBL13401423 | 0.90 | GLP1R (0.40) | GLP1RMMP1MMP3MMP8FURIN | |
| SCHEMBL14012350 | 0.87 | HTT (0.38) | GLP1RFURIN | |
| SCHEMBL26264648 | 0.86 | GLP1R (0.41) | GLP1RFURINMAPTHSD17B10RXFP1 | |
| SCHEMBL13805702 | 0.85 | FURIN (0.32) | GLP1RFURINNPY1RNPY4RHSD17B10 | |
| SCHEMBL13401460 | 0.84 | GLP1R (0.38) | GLP1RFURINRXFP1PRSS1 | |
| SCHEMBL14012359 | 0.83 | HTT (0.37) | GLP1RFURINNPY1RNPY4R | |
| SCHEMBL14012216 | 0.83 | MEN1 (0.41) | GLP1RMAPTHSD17B10 | |
| SCHEMBL25773985 | 0.82 | FURIN (0.40) | MMP1MMP3MMP8FURINCHRNA1 | |
| SCHEMBL22692911 | 0.82 | FURIN (0.40) | FURINNPY1RNPY4RRXFP1CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399403-B2 | drug-ligand conjugates that are potent cytotoxins; stabilized therapeutic agents and markers; exhibit high specificity of action, reduced toxicity, and improved stability in blood ; antitumors | MEDAREX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | MEDAREX, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7691962-B2 | Chemical linkers and conjugates thereof | MEDAREX, INC. (US) | 2010-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | CLSPN, CD74, ANTXR2 | GLP1R 894/4885MMP1 3038/4885MMP3 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.